ProPhase Labs, Inc. announced positive preliminary results from its Equivir dietary supplement comprehensive trial. Preliminary results indicate that this innovative OTC dietary supplement has the potential to support and maintain immunity, which ? if confirmed at the end of the clinical trial program ?

may help reduce both the frequency and severity of upper respiratory illnesses including the common cold, flu, and Covid-19. Conducted by Vedic Life Sciences in India, Equivir is currently being evaluated through two double-blind, placebo-controlled studies. Each study enrolls 150 participants, randomly assigned to receive either Equivir or a placebo, with their health monitored over a 180-day period.

There is an interim look once 150 patients have passed the 90-day mark and a statistically significant number of upper respiratory events (e.g., cold, flu, Covid-19) have occurred. Preliminary results are as follows: Overall, in the initial 150 patient group there were approximately 46 incidences of upper respiratory viral infections. 62.3% of the patients in the placebo group acquired a viral infection versus only 37.7% in the Equivir group.

Additional key statistics from the initial findings are: 39% of the placebo population acquired an upper respiratory viral infection versus 22.9% in the Equivir group. After 4 days of illness, only 3% of the Equivir group still had mild symptoms versus 55% in the placebo group. The average severity was 16% less severe when taking Equivir versus the placebo.

No patients in the Equivir group became ill a second time while 2 patients in the placebo group had a second upper respiratory viral infection. Equivir is being developed with plans to market as an OTC dietary supplement. Therefore, the Company cannot make specific claims regarding Covid-19 treatment or prevention and is not seeking the U.S. Food and Drug Administration?s approval of Equivir as a drug.

However, the Company plans to publish the results when both studies are completed. The Company anticipates that the second trial for Equivir will be completed during Second Quarter 2024. Upon completion of the upcoming second trial, ProPhase Labs aims to leverage its robust distribution channels for a successful product launch, slated for the latter half of 2024.